A Phase III, randomized, open‐label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Issue 6 (May 2014)

• Record Type: Journal Article
• Authors: Hetzel, David; Strauss, William; Bernard, Kristine; Li, Zhu; Urboniene, Audrone; Allen, Lee F.
• Is Part Of: American journal of hematology. Volume 89:Issue 6(2014:Jun.)
• Page Start: 646
• Page End: 650
• Publication Date: 2014-05
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23712
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Iron deficiency anemia (IDA) is the most common form of anemia worldwide. Although oral iron is used as first‐line treatment, many patients are unresponsive to or cannot take oral iron. This Phase III, open‐label, non‐inferiority study compared the efficacy and safety of ferumoxytol, a rapid, injectable intravenous (IV) iron product with low immunological reactivity and minimal detectable free iron, with IV iron sucrose in adults with IDA of any cause. Patients (<italic>N</italic> = 605) were randomized 2:1 to receive ferumoxytol (<italic>n</italic> = 406, two doses of 510 mg 5 ± 3 days apart) or iron sucrose (<italic>n</italic> = 199, five doses of 200 mg on five nonconsecutive days over 14 days) and followed for 5 weeks. Ferumoxytol demonstrated noninferiority to iron sucrose at the primary endpoint, the proportion of patients achieving a hemoglobin increase of ≥2 g dL<sup>−1</sup> at any time from Baseline to Week 5 (ferumoxytol, 84.0% [<italic>n</italic> = 406] vs. iron sucrose, 81.4% [<italic>n</italic> = 199]), with a noninferiority margin of 15%. Ferumoxytol was superior to iron sucrose (2.7 g dL<sup>−1</sup> vs. 2.4 g dL<sup>−1</sup>) in the mean change in hemoglobin from Baseline to Week 5 (the alternative preplanned primary endpoint) with <italic>P</italic> = 0.0124. Transferrin saturation, quality‐of‐life measures, and safety outcomes were similar between the two treatment groups. Overall, ferumoxytol demonstrated comparable safety and efficacy to iron sucrose, suggesting that ferumoxytol may be a useful treatment option for patients with IDA in whom oral iron was unsatisfactory or could not be used. Am. J. Hematol. 89:646–650, 2014. © 2014 Wiley Periodicals, Inc.</p> </abstract>